<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006133</url>
  </required_header>
  <id_info>
    <org_study_id>199/15327</org_study_id>
    <secondary_id>UAB-SELENA</secondary_id>
    <nct_id>NCT00006133</nct_id>
  </id_info>
  <brief_title>Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Research Resources (NCRR)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine the effect of oral contraceptives containing low-dose synthetic
      estrogens and progestins on disease activity in premenopausal women with inactive, stable, or
      moderate systemic lupus erythematosus (SLE).

      II. Determine the effect of hormone replacement therapy with conjugated estrogens and
      progestins on disease activity in postmenopausal women with inactive, stable, or moderate
      SLE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study.
      Patients are stratified according to age/menopausal status (35 and under/premenopausal vs 50
      and over/postmenopausal). Both strata are randomized to one of two treatment arms.

      Stratum 1 (Premenopausal/Oral contraceptives): Patients receive either oral ethinyl estradiol
      and norethindrone or placebo daily for 28 days beginning on the Sunday following the first
      day of the menstrual cycle.

      Stratum 2 (Postmenopausal/Hormone replacement therapy): Patients receive either oral
      estradiol and medroxyprogesterone or placebo on days 1-12 monthly.

      Treatment continues in both arms of both strata for a total of 13 courses in the absence of a
      severe disease flare-up or other complication that would preclude further study
      participation.

      All patients are followed at 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>970</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estradiol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethinyl estradiol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medroxyprogesterone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>norethindrone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Established systemic lupus erythematosus meeting American College of Rheumatology criteria

        Inactive disease Systemic Lupus Erythematosus Activity Index (SLEDAI) score no greater than
        4

        No increase in score of more than 2 from baseline over the past 3 months

        Receiving the equivalent of 5 mg or less of prednisone per day OR Stable/active disease
        SLEDAI score 5-12

        No increase in score of more than 2 from baseline over the past 3 months

        Prednisone dose up to 0.5 mg/kg/day for control of underlying disease allowed if stable
        dose for at least 3 weeks

        No concurrent severe disease activity as defined by any of the following:

          -  Acute renal disease (i.e., rising creatinine levels, cellular sediment, or increasing
             proteinuria)

          -  Involvement of 3 or more organ systems requiring more than the equivalent of 0.5
             mg/kg/day of prednisone

          -  Necessity of immediate hospitalization for symptom control

        No presence of a high titer IgG, IgM, or IgA antiphospholipid antibodies (aPL) GPL and MPL
        no more than 40 APL no more than 50

        No features of primary antiphospholipid antibody syndrome

        --Prior/Concurrent Therapy--

        Biologic therapy: Not specified

        Chemotherapy: Not specified

        Endocrine therapy: See Disease Characteristics

        Radiotherapy: Not specified

        Surgery: Prior hysterectomy allowed

        --Patient Characteristics--

        Age: 35 and under for oral contraceptive stratum (premenopausal) 50 and over for hormone
        replacement therapy stratum (postmenopausal)

        Menopausal status:

          -  Premenopausal for oral contraceptive stratum

          -  Postmenopausal for hormone replacement therapy stratum

          -  Follicle-stimulating hormone greater than 40 mIU/mL OR Amenorrhea for 6 months

        Performance status: See Disease Characteristics

        Hematopoietic: Not specified

        Hepatic:

          -  No hepatic dysfunction

          -  No tumors of the liver

        Renal: See Disease Characteristics

        Cardiovascular:

          -  No uncontrolled high blood pressure requiring frequent change in medication

          -  Concurrent hypertension controlled with stable medication allowed

          -  No history of spontaneous superficial or deep venous thrombosis or arterial thrombosis

          -  No prior myocardial infarction

          -  Oral contraceptive stratum: No angina No diastolic blood pressure greater than 90 mm
             Hg or systolic blood pressure greater than 140 mm Hg on 3 separate determinations

          -  Hormone replacement therapy stratum: No diastolic blood pressure greater than 95 mm Hg
             or systolic blood pressure greater than 145 mm Hg on 3 separate determinations

        Pulmonary: No history of pulmonary embolus

        Other:

          -  Not pregnant

          -  Oral contraceptive stratum: Negative pregnancy test Fertile patients must use
             effective barrier contraception

          -  No prior gynecologic malignancy or breast malignancy

          -  No undiagnosed vaginal bleeding

          -  No diabetes (present prior to use of glucocorticoids) requiring oral hypoglycemic
             medications or insulin

          -  No congenital hyperlipidemia

          -  No complicated migraines (i.e., associated with neurological sequelae)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graciela S. Alarcon</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-6951</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California-San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pritzker School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University School of Medicine</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130-3932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health Systems</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Joint Diseases</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's-Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of Long Island</name>
      <address>
        <city>Port Jefferson Station</city>
        <state>New York</state>
        <zip>11776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas- Houston Medical School</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>August 3, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>arthritis &amp; connective tissue diseases</keyword>
  <keyword>immunologic disorders and infectious disorders</keyword>
  <keyword>rare disease</keyword>
  <keyword>systemic lupus erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

